Iron oxide nanoparticle delivery of peptides to the brain

Reversal of anxiety during drug withdrawal

Nathan Vinzant, Jamie L Scholl, Chia Ming Wu, Trevor Kindle, Ranjit Koodali, Gina L Forster

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Targeting neuropeptide systems is important for future advancements in treatment of neurological and psychiatric illnesses. However, many of the peptides and their analogs do not cross the blood-brain barrier (BBB) efficiently. Nanoparticles such as iron oxide can cross the BBB, and here we describe a novel method for the conjugation of a peptide antisauvagine-30 (ASV-30) to iron oxide nanoparticles. Previous research has shown that direct infusion of ASV-30 into the brain reduces anxiety-like behavior in animal models via actions on corticotropin releasing factor type 2 (CRF2) receptors. Therefore, we tested whether iron oxide+ASV-30 complexes cross the BBB of rats and then determined whether iron oxide+ASV-30 nanoparticles are localized with CRF2-expressing neurons. Finally we tested the hypothesis that systemic infusion of iron oxide+ASV-30 can reduce anxiety-like behavior. First we describe the synthesis and demonstrate the stability of iron oxide-peptide nanoparticle complexes. Next, nanoparticles (87.7 μg/kg Fe2O3) with or without ASV-30 (200 μg/kg, ip) were injected into male rats 30 min prior to transcardial perfusion and brain fixation for immunohistochemical analysis, or before testing on the elevated plus maze (EPM) in an amphetamine withdrawal model of anxiety. Systemically administered iron oxide+ASV-30 particles were present in the brain and associated with neurons, including those that express CRF2 receptors, but did not localize with the iron storage protein ferritin. Furthermore, systemic administration of ironoxide+ASV-30 reduced amphetamine withdrawal-induced anxiety without affecting locomotion, suggesting that the anxiolytic effects of ASV-30 were preserved and the bioavailability of ASV-30 was sufficient. The findings demonstrate a novel approach to peptide delivery across the BBB and provide insight as to the neural distribution and efficacy of this nanotechnology.

Original languageEnglish (US)
Article number608
JournalFrontiers in Neuroscience
Volume11
Issue numberNOV
DOIs
StatePublished - Nov 1 2017

Fingerprint

Nanoparticles
Anxiety
Peptides
Brain
Pharmaceutical Preparations
Blood-Brain Barrier
Amphetamine
antisauvagine 30
ferric oxide
Neurons
Nanotechnology
Corticotropin-Releasing Hormone
Anti-Anxiety Agents
Locomotion
Ferritins
Neuropeptides
Biological Availability
Psychiatry
Iron
Animal Models

Keywords

  • Amphetamine
  • Anxiety
  • Blood brain barrier
  • Corticotropin-releasing factor
  • Iron oxide
  • Nanoparticle

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Iron oxide nanoparticle delivery of peptides to the brain : Reversal of anxiety during drug withdrawal. / Vinzant, Nathan; Scholl, Jamie L; Wu, Chia Ming; Kindle, Trevor; Koodali, Ranjit; Forster, Gina L.

In: Frontiers in Neuroscience, Vol. 11, No. NOV, 608, 01.11.2017.

Research output: Contribution to journalArticle

@article{84e6b550bf8a4e82ae5f97adcc42c92a,
title = "Iron oxide nanoparticle delivery of peptides to the brain: Reversal of anxiety during drug withdrawal",
abstract = "Targeting neuropeptide systems is important for future advancements in treatment of neurological and psychiatric illnesses. However, many of the peptides and their analogs do not cross the blood-brain barrier (BBB) efficiently. Nanoparticles such as iron oxide can cross the BBB, and here we describe a novel method for the conjugation of a peptide antisauvagine-30 (ASV-30) to iron oxide nanoparticles. Previous research has shown that direct infusion of ASV-30 into the brain reduces anxiety-like behavior in animal models via actions on corticotropin releasing factor type 2 (CRF2) receptors. Therefore, we tested whether iron oxide+ASV-30 complexes cross the BBB of rats and then determined whether iron oxide+ASV-30 nanoparticles are localized with CRF2-expressing neurons. Finally we tested the hypothesis that systemic infusion of iron oxide+ASV-30 can reduce anxiety-like behavior. First we describe the synthesis and demonstrate the stability of iron oxide-peptide nanoparticle complexes. Next, nanoparticles (87.7 μg/kg Fe2O3) with or without ASV-30 (200 μg/kg, ip) were injected into male rats 30 min prior to transcardial perfusion and brain fixation for immunohistochemical analysis, or before testing on the elevated plus maze (EPM) in an amphetamine withdrawal model of anxiety. Systemically administered iron oxide+ASV-30 particles were present in the brain and associated with neurons, including those that express CRF2 receptors, but did not localize with the iron storage protein ferritin. Furthermore, systemic administration of ironoxide+ASV-30 reduced amphetamine withdrawal-induced anxiety without affecting locomotion, suggesting that the anxiolytic effects of ASV-30 were preserved and the bioavailability of ASV-30 was sufficient. The findings demonstrate a novel approach to peptide delivery across the BBB and provide insight as to the neural distribution and efficacy of this nanotechnology.",
keywords = "Amphetamine, Anxiety, Blood brain barrier, Corticotropin-releasing factor, Iron oxide, Nanoparticle",
author = "Nathan Vinzant and Scholl, {Jamie L} and Wu, {Chia Ming} and Trevor Kindle and Ranjit Koodali and Forster, {Gina L}",
year = "2017",
month = "11",
day = "1",
doi = "10.3389/fnins.2017.00608",
language = "English (US)",
volume = "11",
journal = "Frontiers in Neuroscience",
issn = "1662-4548",
publisher = "Frontiers Research Foundation",
number = "NOV",

}

TY - JOUR

T1 - Iron oxide nanoparticle delivery of peptides to the brain

T2 - Reversal of anxiety during drug withdrawal

AU - Vinzant, Nathan

AU - Scholl, Jamie L

AU - Wu, Chia Ming

AU - Kindle, Trevor

AU - Koodali, Ranjit

AU - Forster, Gina L

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Targeting neuropeptide systems is important for future advancements in treatment of neurological and psychiatric illnesses. However, many of the peptides and their analogs do not cross the blood-brain barrier (BBB) efficiently. Nanoparticles such as iron oxide can cross the BBB, and here we describe a novel method for the conjugation of a peptide antisauvagine-30 (ASV-30) to iron oxide nanoparticles. Previous research has shown that direct infusion of ASV-30 into the brain reduces anxiety-like behavior in animal models via actions on corticotropin releasing factor type 2 (CRF2) receptors. Therefore, we tested whether iron oxide+ASV-30 complexes cross the BBB of rats and then determined whether iron oxide+ASV-30 nanoparticles are localized with CRF2-expressing neurons. Finally we tested the hypothesis that systemic infusion of iron oxide+ASV-30 can reduce anxiety-like behavior. First we describe the synthesis and demonstrate the stability of iron oxide-peptide nanoparticle complexes. Next, nanoparticles (87.7 μg/kg Fe2O3) with or without ASV-30 (200 μg/kg, ip) were injected into male rats 30 min prior to transcardial perfusion and brain fixation for immunohistochemical analysis, or before testing on the elevated plus maze (EPM) in an amphetamine withdrawal model of anxiety. Systemically administered iron oxide+ASV-30 particles were present in the brain and associated with neurons, including those that express CRF2 receptors, but did not localize with the iron storage protein ferritin. Furthermore, systemic administration of ironoxide+ASV-30 reduced amphetamine withdrawal-induced anxiety without affecting locomotion, suggesting that the anxiolytic effects of ASV-30 were preserved and the bioavailability of ASV-30 was sufficient. The findings demonstrate a novel approach to peptide delivery across the BBB and provide insight as to the neural distribution and efficacy of this nanotechnology.

AB - Targeting neuropeptide systems is important for future advancements in treatment of neurological and psychiatric illnesses. However, many of the peptides and their analogs do not cross the blood-brain barrier (BBB) efficiently. Nanoparticles such as iron oxide can cross the BBB, and here we describe a novel method for the conjugation of a peptide antisauvagine-30 (ASV-30) to iron oxide nanoparticles. Previous research has shown that direct infusion of ASV-30 into the brain reduces anxiety-like behavior in animal models via actions on corticotropin releasing factor type 2 (CRF2) receptors. Therefore, we tested whether iron oxide+ASV-30 complexes cross the BBB of rats and then determined whether iron oxide+ASV-30 nanoparticles are localized with CRF2-expressing neurons. Finally we tested the hypothesis that systemic infusion of iron oxide+ASV-30 can reduce anxiety-like behavior. First we describe the synthesis and demonstrate the stability of iron oxide-peptide nanoparticle complexes. Next, nanoparticles (87.7 μg/kg Fe2O3) with or without ASV-30 (200 μg/kg, ip) were injected into male rats 30 min prior to transcardial perfusion and brain fixation for immunohistochemical analysis, or before testing on the elevated plus maze (EPM) in an amphetamine withdrawal model of anxiety. Systemically administered iron oxide+ASV-30 particles were present in the brain and associated with neurons, including those that express CRF2 receptors, but did not localize with the iron storage protein ferritin. Furthermore, systemic administration of ironoxide+ASV-30 reduced amphetamine withdrawal-induced anxiety without affecting locomotion, suggesting that the anxiolytic effects of ASV-30 were preserved and the bioavailability of ASV-30 was sufficient. The findings demonstrate a novel approach to peptide delivery across the BBB and provide insight as to the neural distribution and efficacy of this nanotechnology.

KW - Amphetamine

KW - Anxiety

KW - Blood brain barrier

KW - Corticotropin-releasing factor

KW - Iron oxide

KW - Nanoparticle

UR - http://www.scopus.com/inward/record.url?scp=85034045693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034045693&partnerID=8YFLogxK

U2 - 10.3389/fnins.2017.00608

DO - 10.3389/fnins.2017.00608

M3 - Article

VL - 11

JO - Frontiers in Neuroscience

JF - Frontiers in Neuroscience

SN - 1662-4548

IS - NOV

M1 - 608

ER -